Company / SG&A Expense
10x Genomics, Inc. SG&A Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$316.1M
FY2025
5-year range
$130.8M / $344.3M
FY2021-FY2025
Trend
-8.2%
vs FY2024
Sector context
#86 of 158
Health Care
What the data says
At $316M, 10x Genomics, Inc.'s sg&a expense ranks #73 of 158 in the Health Care sector. SG&A Expense has fluctuated over the past 9 years, ranging from $47M in FY2017 to $344M in FY2024.
Based on SEC 10-K filings.
$316M in FY2025 with a 5-year CAGR of +9.3%.
Improved from $343M to $316M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +16.0%
- 5-Year CAGR
- +9.3%
- 10-Year CAGR
- -
Sector benchmark
#73 of 158 in Health CareTop 46% of 158This company $316.1M Sector average $175.9B
▼
-99.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +9.3%, indicating consistent growth.
- In FY2025, sg&a expense decreased 8.2% year-over-year.
- Ranks #86 out of 158 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $316.1M | -8.2% |
| FY2024 | $344.3M | +0.3% |
| FY2023 | $343.3M | +69.7% |
| FY2022 | $202.3M | +54.6% |
| FY2021 | $130.8M | -35.3% |
| FY2020 | $202.3M | +54.6% |
| FY2019 | $130.8M | +48.8% |
| FY2018 | $87.9M | +88.2% |
| FY2017 | $46.7M | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026